Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amsterdam Molecular Therapeutics has started collaboration with St Jude Children's Research Hospital in Memphis, Tennessee, US, on the development of a gene therapy treatment for hemophilia B.
Subscribe to our email newsletter
Under the deal, Amsterdam Molecular Therapeutics (AMT) will receive the exclusive commercial rights to the final product. The combination of this gene with AMT’s proprietary adeno-associated virus gene therapy platform could potentially cure this seriously debilitating disease with a single administration of the product. Under the agreement AMT will sponsor research in hemophilia B at St Jude.
Ronald Lorijn, CEO of AMT, said: “Access to the Factor IX gene therapy program perfectly complements our gene therapy platform allowing us to develop an effective and long-lasting therapy for hemophilia B.”